AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2025

Jul 18, 2025

33148_dirs_2025-07-18_ce4e1050-72df-4d8e-a2d4-048d9fd0f5ec.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2025-06-18

Reporting Person: Dolsten Mikael (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-18	Common Stock	A	30000	—	Acquired	44220	Direct

Footnotes

F1: Holdings include 14,220 restricted stock units ("RSUs") that convert to common stock on a one-for-one basis held by the Reporting Person which cliff vest on December 31, 2025.

F2: Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.